Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
ROR
Specific or universal ncRNAs
Universal ncRNAs
Class
Long noncoding RNA
Biomarker
No
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
miR-153-3p/ABCB1
Cancer name
Osteosarcoma
Cancer site
Bone, Articular Cartilage
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
ROR contributed to cisplatin resistance in OS via miR-153-3p/ABCB1 , unraveling a new regulatory network of chemoresistance in cisplatin-resistant OS cells and may provide a therapeutic target for OS patients.
Tissue resource
osteosarcoma tissues and primary osteosarcoma tissues
human osteosarcoma cell lines MG63
human osteosarcoma cell lines U2OS
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Weinan Central Hospital
Cell Bank of the Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.